Cited by 257Hepatocellular Carcinoma Treatment and PrognosisCholangiocarcinoma and Gallbladder Cancer StudiesAlcohol Consumption and Health Effects

Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the Liver Cancer Pooling Project

Open access
Petrick, Jessica L., Campbell, Peter T., Koshiol, Jill, Thistle, Jake E., Andreotti, Gabriella, Beane-Freeman, Laura E., Buring, Julie E., Chan, Andrew T. +24 more·2018·British Journal of Cancer

Abstract

While tobacco and alcohol are established risk factors for hepatocellular carcinoma (HCC), the most common type of primary liver cancer, it is unknown whether they also increase the risk of intrahepatic cholangiocarcinoma (ICC). Thus, we examined the association between tobacco and alcohol use by primary liver cancer type. The Liver Cancer Pooling Project is a consortium of 14 US-based prospective cohort studies that includes data from 1,518,741 individuals (HCC n = 1423, ICC n = 410). Multivariable-adjusted hazards ratios (HRs) and 95% confidence intervals (CI) were estimated using proportional hazards regression. Current smokers at baseline had an increased risk of HCC (hazard ratio (HR) = 1.86, 95% confidence interval (CI): 1.57–2.20) and ICC (HR = 1.47, 95% CI: 1.07–2.02). Among individuals who quit smoking >30 years ago, HCC risk was almost equivalent to never smokers (HR = 1.09, 95% CI: 0.74–1.61). Compared to non-drinkers, heavy alcohol consumption was associated with an 87% increased HCC risk (HR ≥7 drinks/day = 1.87, 95% CI: 1.41–2.47) and a 68% increased ICC risk (HR ≥5 drinks/day = 1.68, 95% CI: 0.99–2.86). However, light-to-moderate alcohol consumption of <3 drinks/day appeared to be inversely associated with HCC risk (HR >0–<0.5 drinks/day = 0.77, 95% CI: 0.67–0.89; HR >0.5–<1 drinks/day = 0.57, 95% CI: 0.44–0.73; HR 1–<3 drinks/day = 0.71, 95% CI: 0.58–0.87), but not ICC. These findings suggest that, in this relatively healthy population, smoking cessation and light-to-moderate drinking may reduce the risk of HCC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41416-018-0007-z

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Smoking is associated with an increased risk of HCC independent of aetiology as well as in MASLD specifically.

    “Smoking has been associated with an increased risk of HCC independent of aetiology 72 as well as in MASLD speci fi cally.”

    From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [72]

    The Discussion reports an increased HCC risk associated with smoking, and the Results report no evidence that the smoking–HCC association was modified by the factors examined. The paper does not establish that the association holds independently of every HCC aetiology; HBV/HCV status was unavailable for some participants. The citation appears before the separate MASLD-specific clause, so that clause is not assessed here. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [31]Rothman KJ Greenland S Lash TL Modern Epidemiology 2008 3rd edn. Philadelphia Wolters Kluwer Health/Lippincott Williams & Wilkins

Cited by

Sorted by citations

Authors
Petrick, J. L., Campbell, P. T., Koshiol, J., Thistle, J. E., Andreotti, G., Beane-Freeman, L. E., Buring, J. E., Chan, A. T., Chong, D. Q., Doody, M. M., Gapstur, S. M., Gaziano, J. M., Giovannucci, E., Graubard, B. I., Lee, I.-M., Liao, L. M., Linet, M. S., Palmer, J. R., Poynter, J. N., Purdue, M. P., Robien, K., Rosenberg, L., Schairer, C., Sesso, H. D., Sinha, R., Stampfer, M. J., Stefanick, M., Wactawski-Wende, J., Zhang, X., Zeleniuch-Jacquotte, A., Freedman, N. D., & McGlynn, K. A.
Affiliations
  • National Cancer Institute (US)
  • American Cancer Society (US)
  • Brigham and Women's Hospital (US)
  • National Cancer Centre Singapore (SG)
  • Harvard University (US)
  • Boston University (US)
  • University of Minnesota (US)
  • George Washington University (US)
  • Stanford Medicine (US)
Corresponding author
Petrick, Jessica L.
Venue
British Journal of Cancer
Published
2018-03-09
Volume
118
Issue
7
Pages
1005-1012
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2789475596
Cited by
257
References
59
Citations by year
2026: 22 · 2025: 37 · 2024: 46 · 2023: 27 · 2022: 46 · 2021: 28 · 2020: 24 · 2019: 21 · 2018: 5
FWCI
12.21
Type
journal article
Language
en
Open access
Locations
  • British Journal of Cancer (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01hl043851-10, CA058420, CA164974, HL-043851, CA-167552, CA 87969, UM1-CA164974)
  • National Heart, Lung, and Blood Institute (R01HL080467, R01‐HL043851, RC1HL099355)
  • National Cancer Institute (CA 058420, K07CA188126, HL-080467, HL-099355, CA-167552, CA-87969, R01CA058420, HL-043851, UM1CA182934, P01CA087969, DK098311, CA-186107, CA164974, CA 047988, UM1CA164974, UM1CA186107, R01CA047988, UM1CA167552, U01CA164974, U01CA167552)
  • National Institute of Diabetes and Digestive and Kidney Diseases (K24DK098311)
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords
hepatocellular carcinoma, intrahepatic cholangiocarcinoma, tobacco use, smoking, alcohol consumption, heavy drinking, light to moderate drinking, smoking cessation, liver cancer risk factors, primary liver cancer
MeSH terms
Adult, Aged, Aged, 80 and over, Alcohol Drinking, Bile Duct Neoplasms, Bile Ducts, Intrahepatic, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Risk Factors, Smoking, Nicotiana, Cohort Studies, Case-Control Studies, Cholangiocarcinoma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review